Phathom Pharmaceuticals, Inc. Return on Tangible Assets

Return on Tangible Assets of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Return on Tangible Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Return on Tangible Assets for 2020 was -53.96% (a -46.44% decrease from previous year)
  • Annual Return on Tangible Assets for 2019 was -100.74% (a -200.58% decrease from previous year)
  • Twelve month Return on Tangible Assets ending September 29, 2021 was -80.8% (a -11.35% decrease compared to previous quarter)
  • Twelve month trailing Return on Tangible Assets increased by 49.74% year-over-year
Trailing Return on Tangible Assets for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-80.8% -91.15% -70.09% -53.96%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Return on Tangible Assets of Phathom Pharmaceuticals, Inc.

Most recent Return on Tangible Assetsof PHAT including historical data for past 10 years.

Interactive Chart of Return on Tangible Assets of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Return on Tangible Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -53.96%
2019 -100.74%
2018 100.16%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.